News
11-28-2012, 12:00 AM
Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.
More... (http://www.news-medical.net/news/20121128/Merrimacke28099s-MM-302-Phase-I-results-and-MM-DX-929-preclinical-data-to-be-presented-at-SABCS.aspx)
More... (http://www.news-medical.net/news/20121128/Merrimacke28099s-MM-302-Phase-I-results-and-MM-DX-929-preclinical-data-to-be-presented-at-SABCS.aspx)